A new OpenAI life‑sciences model, gpt‑rosalind‑discovery, has quietly appeared on the API pricing page, signaling the company’s deeper push into vertical AI markets. The model, launched on October 5 for trusted‑access partners, targets medicinal chemistry and genomics, mirroring OpenAI’s…
Continue reading OpenAI Adds New Life‑Sciences Model as AI‑Driven Drug Discovery Gains MomentumThe AI‑driven drug discovery landscape is heating up on three fronts: new specialised models, virtual trial simulations that are increasingly accurate, and the first generative‑AI‑designed drugs entering late‑stage human trials. OpenAI has quietly added a dedicated life‑sciences model,…
Continue reading Latest News for AI in drug discovery — October 13, 2026Key developments this week include a projected market surge to $17.6 billion by 2031, a $7.7 billion informatics outlook for 2030, and unprecedented activity from frontier AI labs. Anthropic, OpenAI, ByteDance’s Anew Labs and Isomorphic Labs have each launched or…
Continue reading AI‑Driven Drug Discovery Booms in 2026 as Market Grows, Big Labs Deploy Dedicated Models, and Wet‑Lab Capacity Races AheadThe AI‑drug discovery market is set to explode, with forecasts showing a jump from $5.09 billion in 2026 to $17.56 billion by 2031, a 28.1% annual growth rate. This rapid expansion is driven by a wave of frontier AI labs…
Continue reading AI‑Powered Drug Discovery Surge: Market Boom, Lab Bottlenecks, and First Human Trials
